TAIWAN ADVANCED NANOTECH INC. Taiwan Advanced Nanotech Inc. Share Price
Equities
6797
TW0006797004
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.9 TWD | -2.54% |
|
-4.10% | -31.03% |
| Sales 2021 | 1.93B 59.23M 4.94B | Sales 2022 | 1.33B 40.75M 3.4B | Capitalization | 1.77B 54.26M 4.52B |
|---|---|---|---|---|---|
| Net income 2021 | 626M 19.23M 1.6B | Net income 2022 | 326M 10.01M 835M | EV / Sales 2021 | 1.24 x |
| Net cash position 2021 | 465M 14.27M 1.19B | Net cash position 2022 | 697M 21.4M 1.78B | EV / Sales 2022 | 0.81 x |
| P/E ratio 2021 |
4.82
x | P/E ratio 2022 |
5.56
x | Employees | - |
| Yield 2021 |
4.86% | Yield 2022 |
5.11% | Free-Float | 75.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.54% | ||
| 1 week | -4.10% | ||
| Current month | -7.24% | ||
| 1 month | -6.92% | ||
| 3 months | -25.59% | ||
| 6 months | -21.11% | ||
| Current year | -31.03% |
1 week
26.50
28.10
1 month
26.5030.00
Current year
26.5039.70
1 year
26.5063.80
3 years
26.50273.78
5 years
26.50358.04
10 years
26.50358.04
| Managers | Title | Age | Since |
|---|---|---|---|
Raman Chien
FOU | Founder | - | 22/04/22 |
Zhuo Xing Chen
DFI | Director of Finance/CFO | - | - |
I Ping Lo
DFI | Director of Finance/CFO | - | 10/20/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hsiu Miao Huang
BRD | Director/Board Member | - | 12/18/12 |
Chi I Chang
FOU | Founder | - | 22/00/22 |
Raman Chien
FOU | Founder | - | 22/04/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 26.9 | -2.54% | 70,274 |
| 25/24/25 | 27.6 | +0.36% | 30,501 |
| 24/24/24 | 27.5 | +0.36% | 32,336 |
| 23/24/23 | 27.4 | -0.18% | 21,829 |
| 22/24/22 | 27.45 | -2.14% | 101,734 |
End-of-day quote Taipei Exchange, April 26, 2024
More quotes
Taiwan Advanced Nanotech Inc is a Taiwan-based company mainly engaged in provision of automated nucleic acid extraction machines, nanomagnetic bead nucleic acid extraction reagents, automated filling line equipment for DNA/RNA nucleic acid extraction. The main products include SLA series, Maelstrom series and LH series instruments for DNA/RNA nucleic acid extraction; virus nucleic acid extraction reagent 665 series reagents; blood nucleic acid extraction reagent 611/61E series reagents and tissue nucleic acid extraction reagent 6T2/6K2 series reagents. Products are sold to Taiwan, South Korea, China and other countries.
| 1st Jan change | Capi. | |
|---|---|---|
| -31.03% | 25.27M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- 6797 Stock
